Shots:
- Teleflex to acquire BIOTRONIK’s vascular intervention business for ~$797.7M (€760M) in cash, subject to adjustments. Closing expecting in Q3’25
- Acquisition will expand Teleflex’s interventional portfolio with coronary products like Pantera Lux Catheter, PK Papyrus Covered Stent & Orsiro Stent, plus peripheral product like Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent, complementing to its PCI platform
- Acquisition also allows Teleflex to advance development of BIOTRONIK’s Freesolve, which was assessed in BIOMAG-I trial showing superior post 12mos. resorbability & target lesion failure rate with no scaffold thrombosis. Enrolment is ongoing in European BIOMAG-II trial
Ref: Globenewswire | Image: BIOTRONIK
Related News:- Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
